CN110314232A - The composition being made of lipase inhibitor and hydroxy-3-methylglutaryl CoA reductase inhibitor - Google Patents
The composition being made of lipase inhibitor and hydroxy-3-methylglutaryl CoA reductase inhibitor Download PDFInfo
- Publication number
- CN110314232A CN110314232A CN201910714006.8A CN201910714006A CN110314232A CN 110314232 A CN110314232 A CN 110314232A CN 201910714006 A CN201910714006 A CN 201910714006A CN 110314232 A CN110314232 A CN 110314232A
- Authority
- CN
- China
- Prior art keywords
- hydroxy
- inhibitor
- coa reductase
- composition
- methylglutaryl coa
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
The present invention provides a kind of composition being made of lipase inhibitor and hydroxy-3-methylglutaryl CoA reductase inhibitor and containing the pharmaceutical preparation of the composition.Preferably, lipase inhibitor of the present invention is selected from orlistat and west for one of Li Sita；And the hydroxy-3-methylglutaryl CoA reductase inhibitor is selected from one of Atorvastatin, Rosuvastatin, Simvastatin, Fluvastatin, Pravastatin, Lovastatin and Pitavastatin or its pharmaceutically acceptable salt.The antibacterial action that composition of the present invention can generate collaboration simultaneously is acted on the inhibition histamine release cooperateed with, so as to improve the effect and economic feature that bacterium infection causes anaphylactia patient treatment.
Description
Technical field
The invention belongs to pharmaceutical technology fields, and in particular to it is a kind of by lipase inhibitor and hydroxyl first glutaryl coenzyme A also
The composition that reductase inhibitor is constituted and the pharmaceutical preparation containing the composition.
Background technique
Allergy is also referred to as allergic reaction.It is body by antigenicity substance (such as bacterium, virus, helminth, pollen
Deng) stimulation after caused tissue damage or physiological dysfunction.Belong to abnormal or Focal immune response.Usually said
Allergic reaction refers to I type allergic reaction, i.e. type Ⅰ hypersensitivity reaction.Its mechanism is to generate spy after anaphylactogen enters in allergy sufferers body
Anisotropic antibody, the latter are incorporated in the surface of mast cell, make body in sensitization, loose thin when secondary contact allergy original
Born of the same parents' degranulation, and a variety of chemical mediators are discharged, such as serotonin, slow reacting substance, histamine, leukotriene.These media cause
Pathological change or symptom be referred to as type Ⅰ hypersensitivity reaction speed hair phase.
The release of inhibition histamine is one of the main mechanism of a variety of Claritins.
As previously mentioned, bacterium stimulation is one of the reason of leading to allergy, at the same have inhibit histamine release effect and
The drug of antibacterial action will bring beneficial effect for improving the therapeutic effect of the patient of bacterium cause allergy, especially can
Improve the economic feature of its treatment.
It is clinical using Atorvastatin as hydroxyl first glutaryl coenzyme A (HMG-CoA) reductase inhibitor class drug of representative
Upper common regulating plasma lipid medicine, the antibacterial activity of such drug appears in the newspapers announcement repeatly in recent years.Jerwood S et al. researches show that (J
Antimicrob Chemother.2008 Feb；61 (2): 362-4), Simvastatin and Fluvastatin all have certain antibacterial
Effect, wherein the former is respectively 29.2 and 74.9mg/L to the average MIC of MSSA and MRSA, and in contrast, Fluvastatin
Antibacterial action is substantially less than Simvastatin.Welsh AM et al. reports (Pathology.2009；41 (7): 689-91) claim atropic
Cutting down statin and Rosuvastatin also has antibacterial action, but is all remarkably higher than it to the MIC value of MRSA and MSSA and is used to adjust blood
Typical blood concentration when rouge.Masadeh M(Ann Clin Microbiol Antimicrob.2012 May 7；11:13)
Et al. also report the antibacterial action of Atorvastatin, Simvastatin and Rosuvastatin, but its MIC value it is equal > 100mg/L, and
And antibacterial action mechanism is unrelated with hydroxyl first glutaryl coenzyme A.
The research of Krauth MT et al. confirms (Allergy.2006Mar；61 (3): 281-8.), Atorvastatin with
Cerivastatin can inhibit the histamine release of people's mast cell of anti-IgE induction.
It is two kinds of lipase inhibitor class loss of weight drugs that Li Sita (cetilistat) is replaced in orlistat and west, due to fat
Enzyme has expression in various bacteria and regulates and controls the growth and function of bacterium, therefore orlistat may also have certain resist
Bacterium effect, the present inventor also demonstrate this point in laboratory works.
The present inventor is in laboratory work it has also been found that orlistat and west for Li Sita also there is the histamine of moderate to inhibit
Act on
Association is temporarily generated simultaneously without orlistat and hydroxy-3-methylglutaryl CoA reductase inhibitor drug combination in the prior art
The technical teaching of same antibacterial action and the inhibition histamine release effect cooperateed with.
Summary of the invention
The purpose of the present invention is to provide one kind by lipase inhibitor and hydroxy-3-methylglutaryl CoA reductase inhibitor structure
At composition and containing the pharmaceutical preparation of the composition, the composition can generate simultaneously the antibacterial action of collaboration with cooperate with
Inhibition histamine release effect.
To achieve the goals above, present invention firstly provides one kind by lipase inhibitor and hydroxyl first glutaryl coenzyme A
The composition that reductase inhibitor is constituted.
On the one hand preferred, lipase inhibitor of the present invention is selected from orlistat and west for one in Li Sita
Kind；It is furthermore preferred that lipase inhibitor of the present invention is orlistat.
On the one hand preferred, hydroxy-3-methylglutaryl CoA reductase inhibitor of the present invention be selected from Atorvastatin,
One of Rosuvastatin, Simvastatin, Fluvastatin, Pravastatin, Lovastatin and Pitavastatin or its pharmaceutically may be used
The salt of receiving；It is further preferred that hydroxy-3-methylglutaryl CoA reductase inhibitor of the present invention be selected from Simvastatin,
One of rosuvastain calcium, Atorvastatin calcium, Lovastatin, pravastatin sodium, Pitavastatin Calcium and fluvastatin sodium.
On the other hand preferred, lipase inhibitor and HMG-CoA reductase in composition of the present invention
The ratio of the amount of the substance of inhibitor is between 0.008:1~158.489:1.
Another aspect of the present invention provides the pharmaceutical preparation containing composition as previously described.
Preferably, pharmaceutical preparation of the present invention is oral solid formulation.It is furthermore preferred that oral administration solid of the present invention
Preparation is selected from one of capsule, tablet and granule.
Another aspect of the present invention provides foregoing composition and pharmaceutical preparation in preparation for treating bacterium sexuality
Purposes in the drug of dye.
Another aspect of the present invention provides foregoing composition and pharmaceutical preparation in preparation for treating anaphylaxis disease
Purposes in the drug of disease.
Another aspect of the present invention provides foregoing composition and pharmaceutical preparation in preparation simultaneously for treating bacterium
Sexuality dye and the purposes in the drug of anaphylactia.
Preferably, bacterial infection of the present invention be by selected from actinomyces viscosus, bacteroides fragilis, brevibacterium epidermidis,
Infection caused by one of clostridium difficile, clostridium tetani, paratyphosus A bacillus.
Composition of the present invention can generate antibacterial action and the antihistamine release action of collaboration simultaneously.
Specific embodiment
Below with reference to the embodiment of the present invention, clear, complete description is carried out to technical solution of the present invention, it is clear that retouched
The embodiment stated is only a part of the embodiments of the present invention, instead of all the embodiments.Based on the embodiments of the present invention,
Every other embodiment obtained by those of ordinary skill in the art without making creative efforts, belongs to this hair
The range of bright protection.
The ratio of the amount of substance of the present invention is lipase inhibitor and hydroxy-3-methylglutaryl CoA reductase inhibitor
Substance amount ratio.
The present invention indicates the group of the two with "-" connection lipase inhibitor and hydroxy-3-methylglutaryl CoA reductase inhibitor
Close object.
The preparation for the composition that embodiment 1 is made of lipase inhibitor and hydroxy-3-methylglutaryl CoA reductase inhibitor
The lipase inhibitor and hydroxy-3-methylglutaryl CoA reductase inhibitor of the ratio of the amount of predetermined substance are taken, it is sufficiently mixed
Close to get.
The ratio of the amount of substance in test example of the present invention and embodiment include: 0.008:1,0.01:1,0.013:1,
0.016:1、0.02:1、0.025:1、0.032:1、0.04:1、0.05:1、0.063:1、0.079:1、0.1:1、0.126:1、
0.158:1、0.2:1、0.251:1、0.316:1、0.398:1、0.501:1、0.631:1、0.794:1、1:1、1.259:1、
1.585:1、1.995:1、2.512:1、3.162:1、3.981:1、5.012:1、6.31:1、7.943:1、10:1、12.589:1、
15.849:1、19.953:1、25.119:1、31.623:1、39.811:1、50.119:1、63.096:1、79.433:1、100:
1、125.893:1、158.489:1。
The antibacterial of the composition of 1 lipase inhibitor of test example, hydroxy-3-methylglutaryl CoA reductase inhibitor and the two
Effect
Measure lipase inhibitor, hydroxy-3-methylglutaryl CoA reductase inhibitor and fat respectively using filter paper enzyme
Bacteriostatic activity of the enzyme inhibitor-hydroxy-3-methylglutaryl CoA reductase inhibitor to various bacteria.Specifically, being drawn with liquid-transfering gun
Prepared bacterial suspension (1 × 105Preparation method :/mL will live on slant tube culture medium for examination strain
Change [37 ± 1 DEG C, 3 days], recycles oese to beat easily a small amount of lawn from inclined-plane, be respectively added to be contained with 50mL sterile physiological
In the conical flask of salt water), it is uniformly applied to agar plate surface after cooling, plate containing bacterium is made.Sterilizing filter paper piece is taken, respectively
It lets off in the tested material methanol solution of 6 kinds of concentration gradients and impregnates 1h, the 6mm circular filter paper piece impregnated is attached to above-mentioned make
On plate containing bacterium, each culture dish (diameter 90mm) sticks the filter paper of 3 dipped same mass concentration tested material methanol solutions
Piece (filter paper is spaced identical as far as possible), using 50% methanol solution as blank control.Processed plate containing bacterium is placed in 37 DEG C
It is cultivated in insulating box for 24 hours, colony diameter is measured using crossing method, and calculate inhibiting rate (IR) according to following formula.
It is mapped with logarithm of the inhibiting rate (IR) to drug concentration (μM), and carries out linear regression with Excel, according to recurrence
Equation extrapolates the concentration for generating lipase inhibitor and hydroxy-3-methylglutaryl CoA reductase inhibitor when fa inhibits, respectively
ICfa(A)With ICfa(B)Value.For drug combination, then with inhibiting rate (IR) to the concentration (μM) of lipase inhibitor in drug combination
Logarithm (log (c)) mapping, and carries out linear regression with Excel, combined system when extrapolating fa inhibition according to regression equation
The concentration of interior lipase inhibitor, i.e. ICfa(mixA), further according to the ratio of the amount of substance in combined system, when extrapolating fa inhibition
The concentration of hydroxy-3-methylglutaryl CoA reductase inhibitor, i.e. IC in combined systemfa(mixB)。
The drug combination index (CI) generated when fa inhibits is calculated according to the following formula
It when CI < 1, as acts synergistically, CI value is smaller, acts synergistically stronger.
As a result as shown in table 1~6.
Collaboration bacteriostasis of 1 lipase inhibitor of the table-hydroxy-3-methylglutaryl CoA reductase inhibitor to actinomyces viscosus
2 lipase inhibitors of table-hydroxy-3-methylglutaryl CoA reductase inhibitor is to the antibacterial work of the collaboration of bacteroides fragilis
With
3 lipase inhibitors of table-hydroxy-3-methylglutaryl CoA reductase inhibitor is to the antibacterial work of the collaboration of brevibacterium epidermidis
With
Collaboration bacteriostasis of 4 lipase inhibitors of the table-hydroxy-3-methylglutaryl CoA reductase inhibitor to clostridium difficile
5 lipase inhibitors of table-hydroxy-3-methylglutaryl CoA reductase inhibitor is to the antibacterial work of the collaboration of clostridium tetani
With
Collaboration of 6 lipase inhibitors of the table-hydroxy-3-methylglutaryl CoA reductase inhibitor to paratyphosus A bacillus
Bacteriostasis
The composition of 2 lipase inhibitor of test example, hydroxy-3-methylglutaryl CoA reductase inhibitor and the two inhibits histamine
The effect of release
Logarithmic growth phase, RBL-2H3 cell are collected, and its concentration is adjusted to 8 × 104/ mL is uniformly inoculated in 96 holes
In plate, every 200 μ L cell suspension of hole, in 37 DEG C, 5%CO2, saturated humidity incubator in cultivate for 24 hours, discard culture medium, 200
(lipase inhibitor, hydroxy-3-methylglutaryl CoA reductase inhibitor, lipase inhibitor-hydroxyl first glutaryl are auxiliary for μ L tested material
Enzyme A reductase inhibitor is scattered in PBS), while reagent controls group is set, 200 μ L PBS, 37 DEG C of incubations are added in every hole
30min.Be incubated for terminate after, take out 100 μ L of cell conditioned medium be placed in test fluorescent plate in (extra supernatant freezes in -20 DEG C of refrigerators
It deposits, spare), after 50 μ L, 0.4mol/L NaOH is added in each hole of test board, 0.1% o-phthalaldehyde-methanol solution is added immediately
10 μ L are mixed, and are placed at room temperature for 10min, and 50 μ L, 0.5mol/L HCl is added and terminates reaction, (are entered with microplate reader detection A value immediately
Ejected wave long 360nm, launch wavelength 450nm), all tested material groups are calculated as ASupernatant, solvent control group is calculated as ABackground。
Remaining cell is cracked with 0.5% Triton100-PBS solution in 96 orifice plates, after 37 DEG C of incubation 30min, is taken thin
100 μ L of cellular lysate liquid is placed in test fluorescent plate (extra lysate freezes in -20 DEG C of refrigerators, spare), each hole of test board
After 50 μ L, 0.4mol/LNaOH is added, 0.1% o-phthalaldehyde-methanol solution, 10 μ L is added immediately, mixes, is placed at room temperature for
10min is added 50 μ L, 0.5mol/L HCl and terminates reaction, detects A value (incident wavelength with microplate reader immediately after mixing
360nm, launch wavelength 450nm), with A above-mentionedSupernatantThe sum of value is calculated as ASupernatant+cracking, the histamine of each tested material is calculated further according to following formula
It discharges inhibiting rate (IR):
IR (%)=1- (ASupernatant-ABackground)/(ASupernatant+cracking-ABackground) × 100%
It is mapped with logarithm of the inhibiting rate (IR) to drug concentration (μM), and carries out linear regression with Excel, according to recurrence
Equation extrapolates the concentration for generating lipase inhibitor and hydroxy-3-methylglutaryl CoA reductase inhibitor when fa inhibits, respectively
ICfa(A)With ICfa(B)Value.For drug combination, then with inhibiting rate (IR) to the concentration (μM) of lipase inhibitor in drug combination
Logarithm (log (c)) mapping, and carries out linear regression with Excel, combined system when extrapolating fa inhibition according to regression equation
The concentration of interior lipase inhibitor, i.e. ICfa(mixA), further according to the ratio of the amount of substance in combined system, when extrapolating fa inhibition
The concentration of hydroxy-3-methylglutaryl CoA reductase inhibitor, i.e. IC in combined systemfa(mixB)。
The drug combination index (CI) generated when fa inhibits is calculated according to the following formula
It when CI < 1, as acts synergistically, CI value is smaller, acts synergistically stronger.
The results are shown in Table 7.
Table 7
Embodiment 2 contains the composition being made of lipase inhibitor and hydroxy-3-methylglutaryl CoA reductase inhibitor
The preparation of oral solid formulation
Prescription (1000 unit dose)
Preparation method
50g composition and recipe quantity auxiliary material are taken, is sieved with 100 mesh sieve.Take composition, lactose, microcrystalline cellulose, the poly- dimension of crosslinking
Ketone is mixed well with starch；The hydroxypropyl methylcellulose for taking recipe quantity, be configured to according to hydroxypropyl methylcellulose meter concentration be 10% it is molten
The softwood processed into above-mentioned mixed material is added with newborn acid for adjusting pH to 3.0~4.0 in liquid, is pelletized with 16 meshes, and 80 DEG C of dryings 3~
4h.With 16 mesh sieves, the superfine silica gel powder of recipe quantity is added and magnesium stearate mixes mixing, filling capsule is to get capsule；
50g composition and recipe quantity auxiliary material are taken, is sieved with 100 mesh sieve.Take composition, lactose, microcrystalline cellulose, the poly- dimension of crosslinking
Ketone is mixed well with starch；The hydroxypropyl methylcellulose for taking recipe quantity, be configured to according to hydroxypropyl methylcellulose meter concentration be 10% it is molten
The softwood processed into above-mentioned mixed material is added with newborn acid for adjusting pH to 3.0~4.0 in liquid, is pelletized with 16 meshes, and 80 DEG C of dryings 3~
4h.With 16 mesh sieves, the superfine silica gel powder of recipe quantity is added and magnesium stearate mixes mixing, dispenses to get granule；
50g composition and recipe quantity auxiliary material are taken, is sieved with 100 mesh sieve.Take composition, lactose, microcrystalline cellulose, the poly- dimension of crosslinking
Ketone is mixed well with starch；The hydroxypropyl methylcellulose for taking recipe quantity, be configured to according to hydroxypropyl methylcellulose meter concentration be 10% it is molten
The softwood processed into above-mentioned mixed material is added with newborn acid for adjusting pH to 3.0~4.0 in liquid, is pelletized with 16 meshes, and 80 DEG C of dryings 3~
4h.With 16 mesh sieves, the superfine silica gel powder of recipe quantity is added and magnesium stearate mixes mixing, tabletting both obtains tablet.
Claims (10)
1. a kind of composition being made of lipase inhibitor and hydroxy-3-methylglutaryl CoA reductase inhibitor.
2. composition according to claim 1, which is characterized in that the lipase inhibitor is to replace selected from orlistat with west
One of Li Sita；It is furthermore preferred that the lipase inhibitor is orlistat.
3. composition according to claim 1, which is characterized in that the hydroxy-3-methylglutaryl CoA reductase inhibitor is choosing
From one of Atorvastatin, Rosuvastatin, Simvastatin, Fluvastatin, Pravastatin, Lovastatin and Pitavastatin
Or its pharmaceutically acceptable salt；It is furthermore preferred that the hydroxy-3-methylglutaryl CoA reductase inhibitor is to cut down him selected from pungent
One in spit of fland, rosuvastain calcium, Atorvastatin calcium, Lovastatin, pravastatin sodium, Pitavastatin Calcium and fluvastatin sodium
Kind.
4. composition according to claim 1~any one of 3, which is characterized in that the lipase inhibitor and hydroxyl first penta
The ratio of the amount of the substance of two acyl coenzyme A reductase inhibitors is between 0.008:1~158.489:1.
5. the pharmaceutical preparation containing composition according to claim 1~any one of 4.
6. pharmaceutical preparation according to claim 5, which is characterized in that the pharmaceutical preparation is oral solid formulation.It is furthermore preferred that
Oral solid formulation of the present invention is selected from one of capsule, tablet and granule.
7. composition according to claim 1~any one of 4 or the drug system according to any one of claim 5~6
Agent is preparing the purposes in the drug for treating bacterial infection.
8. composition according to claim 1~any one of 4 or the drug system according to any one of claim 5~6
Agent is preparing the purposes in the drug for treating anaphylactia.
9. composition according to claim 1~any one of 4 or the drug system according to any one of claim 5~6
Agent is preparing while being used to treat the purposes in bacterial infection and the drug of anaphylactia.
10. according to claim 7 and any one of 9 purposes, which is characterized in that the bacterial infection is by selected from viscous
Caused by one of actinomyces, bacteroides fragilis, brevibacterium epidermidis, clostridium difficile, clostridium tetani, paratyphosus A bacillus
Infection.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910714006.8A CN110314232A (en) | 2019-08-03 | 2019-08-03 | The composition being made of lipase inhibitor and hydroxy-3-methylglutaryl CoA reductase inhibitor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910714006.8A CN110314232A (en) | 2019-08-03 | 2019-08-03 | The composition being made of lipase inhibitor and hydroxy-3-methylglutaryl CoA reductase inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110314232A true CN110314232A (en) | 2019-10-11 |
Family
ID=68125314
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910714006.8A Pending CN110314232A (en) | 2019-08-03 | 2019-08-03 | The composition being made of lipase inhibitor and hydroxy-3-methylglutaryl CoA reductase inhibitor |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110314232A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110746381A (en) * | 2019-11-16 | 2020-02-04 | 中山万汉制药有限公司 | Eutectic crystal composed of orlistat and proton pump inhibitor, composition and application thereof |
| CN110812363A (en) * | 2019-11-16 | 2020-02-21 | 中山万汉制药有限公司 | Composition containing trisubstituted phosphine oxide and oxetanone derivative and use thereof |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008143491A1 (en) * | 2007-05-21 | 2008-11-27 | Espinosa Abdala Leopoldo De Je | Pharmaceutical compositions combining a hydrogenated lipstatin derived agent and a hmg-coa reductase inhibiting agent |
| EP2179732A1 (en) * | 2007-06-15 | 2010-04-28 | Espinosa Abdala, Leopoldo de Jesús | Pharmaceutical composition combining an enzyme hmg-coa reductase inhibiting agent and a gastrointestinal lipase enzyme inhibiting agent |
| CN101756990A (en) * | 2008-11-10 | 2010-06-30 | 鲁南制药集团股份有限公司 | Medical composition for losing weight or treating hyperlipidemia |
| CN101795684A (en) * | 2007-04-09 | 2010-08-04 | 赛多斯有限责任公司 | Combinations of statins and anti-obesity agent |
| CN106955357A (en) * | 2017-05-22 | 2017-07-18 | 张凌 | A kind of compound orlistat composite preparation lost weight for pet and its application |
| CN109276719A (en) * | 2018-11-01 | 2019-01-29 | 中山万汉制药有限公司 | Composition containing orlistat nanoparticle and kinases inhibitor |
-
2019
- 2019-08-03 CN CN201910714006.8A patent/CN110314232A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101795684A (en) * | 2007-04-09 | 2010-08-04 | 赛多斯有限责任公司 | Combinations of statins and anti-obesity agent |
| WO2008143491A1 (en) * | 2007-05-21 | 2008-11-27 | Espinosa Abdala Leopoldo De Je | Pharmaceutical compositions combining a hydrogenated lipstatin derived agent and a hmg-coa reductase inhibiting agent |
| EP2179732A1 (en) * | 2007-06-15 | 2010-04-28 | Espinosa Abdala, Leopoldo de Jesús | Pharmaceutical composition combining an enzyme hmg-coa reductase inhibiting agent and a gastrointestinal lipase enzyme inhibiting agent |
| CN101756990A (en) * | 2008-11-10 | 2010-06-30 | 鲁南制药集团股份有限公司 | Medical composition for losing weight or treating hyperlipidemia |
| CN106955357A (en) * | 2017-05-22 | 2017-07-18 | 张凌 | A kind of compound orlistat composite preparation lost weight for pet and its application |
| CN109276719A (en) * | 2018-11-01 | 2019-01-29 | 中山万汉制药有限公司 | Composition containing orlistat nanoparticle and kinases inhibitor |
Non-Patent Citations (3)
| Title |
|---|
| EMMA HENNESSY ET AL: "Is There Potential for Repurposing Statins as Novel Antimicrobials?", 《ANTIMICROBIAL AGENTS AND CHEMOTHERAPY》 * |
| KRAUTH, MT ET AL: "Effects of various statins on cytokine-dependent growth and IgE-dependent release of histamine in human", 《ALLERGY》 * |
| 喻友军等主编: "《实用传染科医师处方手册》", 30 September 2004, 科学技术文献出版社 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110746381A (en) * | 2019-11-16 | 2020-02-04 | 中山万汉制药有限公司 | Eutectic crystal composed of orlistat and proton pump inhibitor, composition and application thereof |
| CN110812363A (en) * | 2019-11-16 | 2020-02-21 | 中山万汉制药有限公司 | Composition containing trisubstituted phosphine oxide and oxetanone derivative and use thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ochiai et al. | Inhibitory effect of bafilomycin A1, a specific inhibitor of vacuolar-type proton pump, on the growth of influenza A and B viruses in MDCK cells | |
| CN110314232A (en) | The composition being made of lipase inhibitor and hydroxy-3-methylglutaryl CoA reductase inhibitor | |
| CN109475757A (en) | The phenolic compound that electrophilic for treating inflammation related disease and disorder enhances | |
| Fedorov et al. | Dactylone inhibits Epidermal Growth Factor–induced transformation and phenotype expression of human cancer cells and induces G1-S arrest and apoptosis | |
| CN108853358B (en) | Antibacterial traditional Chinese medicine composition and preparation method and application thereof | |
| Huerta et al. | Herbs, spices and medicinal plants used in hispanic traditional medicine can decrease quorum sensing dependent virulence in Pseudomonas aeruginosa | |
| CN104145966A (en) | Application of chelerythrine in preparation of antifungal biofilm medicines | |
| CN1230173C (en) | Preventives and remedies for complications of diabetes | |
| CN110357812A (en) | The eutectic compound being made of lipase inhibitor and hydroxy-3-methylglutaryl CoA reductase inhibitor | |
| CN109276719A (en) | Composition containing orlistat nanoparticle and kinases inhibitor | |
| CN109939098A (en) | Application of the flavone c-glycosides in the product that preparation inhibits bacterial community induction | |
| CN107929742A (en) | The anti-infective pharmaceutical applications of hordenine or its joint antibiotic | |
| CN102724977B (en) | Fulvic acid in combination with fluconazole or amphotericin b for the treatment of fungal infections | |
| CN110302201B (en) | Application of styryl quinoline derivative in preparation of drug-resistant bacterium resisting medicine and drug-resistant bacterium resisting medicine | |
| CN110025621A (en) | Tizoxanide and Nitazoxanide application in preparing anti-inflammatory drugs | |
| CN106176700A (en) | Niclosamide application in preparing anti-tumorigenesis herpesvirus medicament | |
| CN109999045A (en) | The application of tizoxanide and Nitazoxanide in preparation novel autophagy derivant | |
| CN105395538B (en) | A kind of pharmaceutical composition treating acute upper respiratory tract infection | |
| CN110812359A (en) | Application of chelerythrine in preparation of medicines for inhibiting biological envelopes of candida albicans and staphylococcus aureus | |
| CN110839635A (en) | Compound pesticide of nicotine and tea saponin and application of compound pesticide in prevention and treatment of myzus persicae | |
| CN109528710A (en) | Composition containing tolylthiophene class compound | |
| LU504544B1 (en) | Application of extract from leaves of nauclea officinalis in preparation of drug for resisting candida krusei | |
| Shruthi et al. | In vitro antibacterial activities of Kirganelia reticulata baill. against Methicilin-Resistant Staphilococcus aureus | |
| CN106806367A (en) | A kind of pharmaceutical composition for treating infections after burn | |
| Titiladunayo et al. | In silico and In vitro combinatorial study in the fight against the multi-drug resistant uropathogen, Pseudomonas aeruginosa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20191011 |
|
| RJ01 | Rejection of invention patent application after publication |